CVKD Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Cadrenal Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCVKD

Market Cap13.9M

Cash RunwayRunway < 6 months

Next CatalystCorporate Update

Public Research Snapshot

Cadrenal Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Redefining What’s Possible (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
CAD-1005	n/a	n/a	Pivotal	Public pipeline row
Redefining What’s Possible	n/a	n/a	Phase 3	Public pipeline row
Frunexian	n/a	Small Molecule	n/a	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Corporate Update	December 2025	n/a	Low
		FDA Meeting	Timing not specified	CAD-1005	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

catalyst_type | Corporate Update
catalyst_type | Corporate Update
catalyst_type | Corporate Update
catalyst_type | Corporate Update
catalyst_type | Corporate Update

Want the full CVKD research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.